EDAP TMS SA current report, Q4 FY2024

EDAP TMS SA - Q3 2024 Financial Summary

Business Context and Reporting Period

This Form 6-K filing reports the unaudited consolidated financial results for EDAP TMS SA for the third quarter and nine months ended September 30, 2024. EDAP TMS is a global leader in robotic energy-based therapies, primarily focused on its Focal One High-Intensity Focused Ultrasound (HIFU) platform for prostate cancer treatment, as well as lithotripsy and distribution businesses.

Key Financial Metrics

Metric Q3 2024 (EUR) Q3 2023 (EUR) YTD 2024 (EUR) YTD 2023 (EUR)
Total Revenue 13.1 million 11.7 million 43.8 million 40.8 million
Gross Profit 5.2 million 4.2 million 17.5 million 15.8 million
Gross Margin 39.4% 35.5% 39.9% 38.8%
Operating Loss (5.8) million (5.6) million (16.8) million (16.3) million
Net Loss (6.4) million (3.9) million (17.1) million (16.1) million
Cash & Equivalents 25.5 million (Sep 30, 2024) 43.5 million (Dec 31, 2023) N/A

Segment Performance (Q3 2024):

  • HIFU: Revenue of EUR 4.5 million (up 48.2% YoY); 3 systems sold.
  • Distribution: Revenue of EUR 6.6 million (up 10.0% YoY).
  • LITHO: Revenue of EUR 2.0 million (down 25.9% YoY); 3 units sold vs. 7 in prior year.

Material Changes vs. Prior Period

  • Revenue Growth: Total revenue increased 11.6% in Q3 and 7.3% YTD, driven primarily by a 48.2% surge in HIFU revenue and 35.3% growth in worldwide disposables.
  • Margin Expansion: Gross margin improved to 39.4% in Q3 (from 35.5%) due to favorable product mix and better absorption of fixed costs.
  • Expense Increase: Operating expenses rose to EUR 11.0 million in Q3 (from EUR 9.7 million) due to investments in global Focal One commercial operations.
  • Liquidity Decline: Cash and cash equivalents decreased from EUR 43.5 million at year-end 2023 to EUR 25.5 million as of September 30, 2024. Net cash used in operating activities for the nine months ended September 30, 2024, was EUR 14.8 million.

Guidance, Outlook, and Strategic Updates

  • Reimbursement: CMS finalized a 5.4% increase in the Medicare Hospital payment rate for Focal One HIFU procedures to $9,247 for 2025, supporting the business case for hospital adoption.
  • AI Collaboration: Announced a partnership with Avenda Health to integrate "Unfold AI" into the Focal One robotic system for personalized prostate cancer care.
  • Clinical Pipeline:
    • BPH: First patients treated in Phase I/II study for Benign Prostatic Hyperplasia.
    • Endometriosis: Phase 3 interim results showed excellent safety and significant lesion volume reduction, though the primary endpoint for acute pain reduction at 3 months was not met. Over 85% of Sham arm patients elected to cross over to HIFU treatment.
  • Outlook: Management expects a strong finish to 2024, citing a strong pipeline and the closure of the first Focal One system to an HCA hospital in Q4.
  • Corporate Governance: Lance Willsey, M.D., appointed Interim Chairman of the Board; Fran Schulz appointed to the Board of Directors.

Investor Verification Checklist

  • Verify the sustainability of the 48.2% HIFU revenue growth rate given the small absolute base (EUR 4.5M).
  • Monitor cash burn rate; cash reserves dropped by approximately EUR 18 million in nine months.
  • Assess the impact of the Phase 3 Endometriosis trial results on future regulatory pathways and commercial potential.
  • Confirm the timeline for the commercial rollout of the Avenda Health AI integration.
  • Review the LITHO segment decline (25.9% drop in Q3) to determine if this is a cyclical dip or a structural market shift.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.